Profile data is unavailable for this security.
About the company
JW (Cayman) Therapeutics Co Ltd is a company primarily engaged in research and development, manufacturing, and marketing of cellular immunotherapy products. The Company has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. The Company’s main product, Carteyva, is an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) cell immunotherapy product independently developed by the Company based on a CAR-T cell process platform of Juno (a Bristol Myers Squibb company). The Company mainly conducts its business in the domestic market.
- Revenue in HKD (TTM)190.72m
- Net income in HKD-692.44m
- Incorporated2017
- Employees323.00
- LocationJW (Cayman) Therapeutics Co LtdNo 225 Meisheng RoadPilot Free Trade Zone, 4f, Building 42SHANGHAI KY1-1104ChinaCHN
- Websitehttps://www.jwtherapeutics.com/
More ▼